Key result
LOXBlock-1 reduces infarct size and tPA-associated hemorrhage in ischemic stroke models.
Answers are grounded in this paper and cite their sources.
Demonstrates that 12/15-lipoxygenase inhibition protects ischemic brain tissue and reduces hemorrhage in stroke models, suggesting a viable first-line acute therapy.
Targeting newly identified damage pathways in the ischemic brain can help to circumvent the currently severe limitations of acute stroke therapy. Here we show that the activity of 12/15-lipoxygenase was increased in the ischemic mouse brain, and 12/15-lipoxygenase colocalized with a marker for oxidized lipids, MDA2. This colocalization was also detected in the brain of 2 human stroke patients, where it also coincided with increased apoptosis-inducing factor. A novel inhibitor of 12/15-lipoxygenase, LOXBlock-1, protected neuronal HT22 cells against oxidative stress. In a mouse model of transient focal ischemia, the inhibitor reduced infarct sizes both 24 hours and 14 days poststroke, with improved behavioral parameters. Even when treatment was delayed until at least 4 hours after onset of ischemia, LOXBlock-1 was protective. Furthermore, it reduced tissue plasminogen activator-associated hemorrhage in a clot model of ischemia/reperfusion. This study establishes inhibition of 12/15-lipoxygenase as a viable strategy for first-line stroke treatment.
No takes yet. Share an insight, caveat, or question.
Yiğitkanlı et al. (2012) studied Ischemic stroke. 12/15-lipoxygenase inhibitor (LOXBlock-1) vs. Control/vehicle (implied) was evaluated on Infarct size, behavioral parameters, and hemorrhage. The novel 12/15-lipoxygenase inhibitor LOXBlock-1 reduced infarct sizes, improved behavioral parameters, and decreased tissue plasminogen activator-associated hemorrhage in models of ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: